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Objective: Toll like receptor 4 (TLR4) plays a key role in inﬂammation and previously it was established
that TLR4 deﬁciency attenuates atherosclerosis. RadioProtective 105 (RP105) is a structural homolog of
TLR4 and an important regulator of TLR4 signaling, suggesting that RP105 may also be an important
effector in atherosclerosis. We thus aimed to determine the role of RP105 in atherosclerotic lesion
development using RP105 deﬁcient mice on an atherosclerotic background. Methods and results:
Atherosclerosis was induced in Western-type diet fed low density lipoprotein receptor deﬁcient (LDLr/
) and LDLr/RP105 double knockout (LDLr//RP105/) mice by means of perivascular carotid artery
collar placement. Lesion size was signiﬁcantly reduced by 58% in LDLr//RP105/ mice, and moreover,
plaque macrophage content was markedly reduced by 40%. In a model of acute peritonitis, monocyte
inﬂux was almost 3-fold reduced in LDLr//RP105/ mice (P ¼ 0.001), while neutrophil inﬂux
remained unaltered, suggestive of an altered migratory capacity of monocytes upon deletion of RP105.
Interestingly, in vitro stimulation of monocytes with LPS induced a downregulation of CCR2, a chemokine
receptor crucially involved in monocyte inﬂux to atherosclerotic lesions, which was more pronounced in
LDLr//RP105/monocytes as compared to LDLr/monocytes. Conclusion: We here show that RP105
deﬁciency results in reduced early atherosclerotic plaque development with a marked decrease in
lesional macrophage content, which may be due to disturbed migration of RP105 deﬁcient monocytes
resulting from CCR2 downregulation.
© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Atherosclerotic lesions in the large and medium sized arteries
are the major cause of cardiovascular events and complications
worldwide [1]. It has beenwell established that inﬂammation plays
a key role in the initiation, growth and rupture of an atherosclerotic
plaque [2e5]. Early steps in this process involve the adhesion of
monocytes to dysfunctional endothelium, where they subsequently
migrate into the vessel wall and take up oxidized LDL [6]. Inﬂux of
additional inﬂammatory cells from both the innate and adaptiveiden University Medical Cen-
.
rved.immune system, such as dendritic cells, T cells and mast cells,
further aggravates lesion formation [7,8].
Toll-like receptors (TLRs) are the primary receptors of the innate
immune system: they recognize highly conserved molecular motifs
called pathogen associated molecular patterns (PAMPs) as well as
endogenous damage-associatedmolecular patterns (DAMPs) [9,10].
TLR4, one of the most characterized receptors of the TLR family, has
been subjected to extensive research regarding its role in athero-
sclerosis. Atherosclerosis prone mice deﬁcient for TLR4 develop
smaller atherosclerotic lesions [11], while also antagonism of TLR4
results in reduced early lesion formation [12]. RadioProtective 105
(RP105) is a TLR homolog capable of regulating TLR4 signaling.
RP105 is structurally similar to TLR4, but lacks the intracellular Toll
Interleukin Receptor (TIR) signaling domain. Originally, RP105 was
A. Wezel et al. / Atherosclerosis 238 (2015) 132e139 133described as a B cell speciﬁc molecule, able to drive cellular pro-
liferation and to enhance B cell dependent inﬂammatory processes
[13,14]. However, additional research revealed that the expression
of RP105 on antigen presenting cells directlymirrors that of TLR4, in
which it acts as a negative regulator. Consequently, LPS injection in
RP105 deﬁcient mice results in an exaggerated inﬂammatory
response [15], and the inhibitory effect of RP105 on TLR4 responses
is thought to be exerted via a direct extracellular interaction with
TLR4 [16,17].
Because of the opposite regulatory role that RP105 seems to play
in different cell types, it is compelling to study the effect of RP105
deﬁciency in inﬂammatory diseases including atherosclerotic
vascular remodeling. Previously, we have demonstrated that in a
hyperlipidemic setting, lethally irradiated mice receiving RP105/
bone marrow display an unexpected decrease in plaque size. This
reduction in atherosclerosis was mainly explained by decreased B
cell activation, proliferation and immunoglobulin production [18].
These data would suggest that deﬁciency of RP105 is a novel route
via which atherosclerosis can be inhibited. However, we have also
shown that lack of RP105 results in increased neointima formation
in a mouse model for damage induced post-interventional vascular
remodeling [19]. Smooth muscle cells deﬁcient for RP105 display
increased proliferation following LPS stimulation, which may
explain the increase in neointima formation. These opposing roles
of RP105 on smooth muscle cells and B cells make it difﬁcult to
conclude on the effect of total body RP105 deﬁciency on athero-
sclerosis, since both cell types are known to contribute to lesion
formation. Therefore, it remains to be studied whether the contri-
bution of RP105 mediated smooth muscle cell proliferation or
RP105 dependent changes in leukocyte function play a more pre-
dominant role in atherosclerosis.
In the current studywe thus aim to investigatewhat the effect of
total body RP105 deﬁciency is on atherosclerosis. Also, we deter-
mined how RP105 expression is regulated during the process of
atherosclerotic lesion formation.
2. Material and methods
2.1. Mouse atherosclerosis time course
All animal work was approved by the animal welfare committee
of the Leiden University Medical Center and mice were bred in our
facility at the Gorlaeus Laboratories (Leiden, the Netherlands). For
the generation of a mouse atherosclerosis time course, male LDLr/
 were fed a Western type diet (0.25% cholesterol and 15% cacao
butter, SDS, Sussex, UK) starting two weeks before surgery and
throughout the experiment. Mice were anaesthetized by subcu-
taneous injection of ketamine (60 mg/kg, Eurovet Animal Health,
Bladel, The Netherlands), fentanyl citrate and ﬂuanisone (1.26 mg/
kg and 2 mg/kg respectively, Janssen Animal Health, Sauderton,
UK). All mice received perivascular collars around the carotid artery
to induce plaque formation as previously described [20]. In brief, a
semi-constrictive collar was placed around both carotid arteries of
the mice two weeks after start of the Western type diet. Disturbed
ﬂow at the proximal site of the collar results in endothelial acti-
vation with subsequent atherosclerotic lesion formation.
Gene expression proﬁles of carotid artery plaques in LDLr/
mice were determined at 0e8 weeks after perivascular collar
placement. Hereto, a subset of mice was sacriﬁced at the time
points indicated below. Fixation through the left cardiac chamber
was performed with phosphate-buffered saline (PBS). Subse-
quently, both common carotid arteries were excised and snap-
frozen in liquid nitrogen for optimal RNA preservation. A sche-
matic overview of the mouse atherosclerosis time course is
depicted in Suppl. Fig. 1A. For RNA isolation, two to three carotidartery segments carrying the plaque from 0, 2, 4, 6, or 8 weeks after
collar placement were pooled for each sample and homogenized by
grounding in liquid nitrogenwith a pestle. Of each time point, three
samples of pooled carotids were obtained for RNA extraction. Total
RNA was extracted from the tissue homogenates using Trizol re-
agent according to manufacturer's instructions (Invitrogen, Breda,
The Netherlands). Gene expression levels were determined using
an Illumina Bead-Chip Whole Genome Microarray (ServiceXS,
Leiden, The Netherlands).
2.2. Atherosclerosis in LDLr//RP105/ versus LDLr/ mice
RP105/ mice were kindly provided by K. Miyake (Tokyo Uni-
versity, Japan) and were described previously [21]. Male LDLr/
(n ¼ 12) and male LDLr//RP105/ mice (LDLr/ background,
backcrossed for more than 10 generations) (n ¼ 12) bred in our
laboratory (Gorlaeus Laboratories), were fed a Western type diet
throughout the experiment. After two weeks of diet feeding, body
weight was measured and plasma total cholesterol levels were
determined by incubation with 0.025 U/mL cholesterol oxidase
(Sigma, Zwijndrecht, The Netherlands) and 0.065 U/mL peroxidase
and 15 mg/mL cholesterol esterase (Roche Diagnostics, Mannheim,
Germany) in polyoxyethylene-9-laurylether, and 7.5% methanol).
Precipath was used as an internal standard (standardized serum;
Boehringer, Mannheim, Germany) and absorbance was read at
490 nm. At that time-point, mice were anaesthetized and collars
were placed as described in the previous section, after which le-
sions were allowed to develop for another four weeks (schematic
overview in Suppl. Fig. 1B). At sacriﬁce, four weeks after collar
placement, in situ ﬁxation through the left cardiac chamber was
performed, after which carotid artery lesion size and morphology
were analyzed.
2.3. Histology and morphometry
Parafﬁn embedded carotid plaques were cut in sections of 5 mm
thick and stained with hematoxylin-phloxine-saffron (HPS) to
determine lesion size. (Immuno)histochemical staining was per-
formed for macrophages (MAC3; 1:200; BD-Pharmingen, San
Diego, USA), alpha smooth muscle cell actin (1:1000; Sigma),
collagen (picrosirius red staining) and CCR2 (1:400; Abcam, Cam-
brigde, UK). An enzymatic staining (CAE, Sigma) was used for
visualizing mast cells.
Morphometric analysis (Leica Qwin image-analysis software)
was performed at site of maximal stenosis. (Immuno)histochemical
stainings were quantiﬁed by computer assisted analysis (Leica,
Qwin, Cambridge, UK) and expressed as the percentage of positive
stained area of the total intimal area. Perivascular mast cells were
counted manually and scored as either resting when all granula
were inside the cell, or activated when granula were deposited in
the tissue surrounding the mast cell.
2.4. Flow cytometry
At sacriﬁce, blood was collected and peritoneal cells were iso-
lated (n ¼ 5/group) by ﬂushing the peritoneal cavity with 10 mL
PBS. Erythrocytes were removed using an erythrocyte lysis buffer
(pH 7.3). Blood cells were stained with CD11b; Ly6C; Ly6G to
determine the amount of neutrophils and monocytes. CD4; CD8;
CD25; CD19 antibodies were used to detect T and B cells. Peritoneal
cells were stained to analyze B cells (CD19þ), B cell subsets (B1
cells: CD5þ; CD4; IgMþ, and B2 cells: IgM; IgDþ, both calculated
as a percentage of CD19þ cells), and mast cells (CD117; IgE; FcgR;
FcεRI). FACS analysis was performed on a FACSCantoII (BD-
Fig. 1. RP105 deﬁciency results in reduced plaque size. After 2, 3 and 6 weeks of diet, no changes were seen in cholesterol levels and weight between LDLr//RP105/mice and
LDLr/ control mice (A). FACS analysis of the blood at time of sacriﬁce revealed no changes in monocytes (CD11bþ; Ly6Glow), neutrophils (CD11bþ; Ly6Ghigh) or B cells (CD19þ)
between LDLr//RP105/ mice and control LDLr/ mice (B). Plaque size was signiﬁcantly reduced in LDLr//RP105/ mice compared to LDLr/ mice (C). Micrographs show
representative images of each group (100). N ¼ 12 mice/group. *P < 0.05. A 2-tailed Student's t-test was used to compare individual groups.
A. Wezel et al. / Atherosclerosis 238 (2015) 132e139134Biosciences, San Jose, USA) and data were analyzed using FACSDiva
software.
2.5. Serum immunoglobulin detection and MCP-1 levels
IgM, IgG1 and IgG2a levels in serumwere detected with the use
of a mouse immunoglobulin isotyping ELISA kit according to
manufacturer's protocol (BD Biosciences). Total IgE in serum was
determined by a mouse IgE quantitative ELISA (Bethyl Laboratories,
Montgomery, USA). To detect MCP-1 in serum an ELISA was per-
formed according to manufacturer's protocol (BD-Biosciences).
2.6. In vivo inﬂux to peritoneum
LDLr//RP105/ and LDLr/mice (n¼ 5/group) were injected
intra-peritoneal with 1 mL 3% Brewer's thioglycollate (Difco) or
1 mL PBS as a control. Five days after injection the peritoneal cavity
was ﬂushed with 10 mL PBS, cells were centrifuged for 5 min at
1500 rpm and resuspended in 1 mL PBS. Flow cytometry was used
to analyze monocyte numbers (CD11b; Ly6G; Ly6C), monocyte
chemokine receptor expression (CD11b; CCR2; CX3CR1) and mac-
rophages numbers (F4/80; CD40; CD80). FACS analysis was per-
formed on a FACSCantoII (BectoneDickinson) and data were
analyzed using FACSDiva software.
2.7. Cell culture
Bone marrow (BM) derived monocytes were isolated and
differentiated as described previously [22]. In brief, BMwas isolated
by ﬂushing femurs and tibias with PBS. Cells were cultured for 5days in RPMI 1640 medium supplemented with 10% FCS, 2 mmol/L
L-glutamine, 100 U/mL penicillin and 100 mg/mL streptomycin and
20 ng/mL recombinant murine M-CSF (eBioscience, San Diego,
USA) to generate BM-derived monocytes. After 5 days, non-
adherent cells were harvested and analyzed by FACS for CD11b
and Ly6C expression to determine monocyte purity, which reached
approximately 84%.
BM derived monocytes (106 cells) were stimulated with LPS (1
or 10 ng/mL, from E. Coli, Sigma) or control medium overnight at
37 C, after which cells were harvested for RNA isolation.
For FACS analysis of CCR2 and CCR5 expression on monocytes,
cells were stimulated for 2 h with LPS (1 or 10 ng/mL) and stained
with antibodies for CD11b; Ly6C; CCR2; CCR5.
2.8. RNA isolation and cDNA synthesis
RNAwas isolated using a standard TRIzol-chloroform extraction
protocol after which RNA was examined by nanodrop (Nanodrop®
Technologies). Relative quantitative mRNA PCR was performed on
reverse transcribed cDNA using Taqman gene expression assays
and qPCRs were run on a 7900HT Fast Real-Time PCR System
(Applied Biosystems, Foster City, USA). The relative expression of
CCR2, CCR5, CCR1 and CX3CR1 was determined using the murine
housekeeping genes HPRT, RPL27, B-actin (Suppl. Table 1).
2.9. Statistical analysis
Data are expressed as mean ± SEM. A 2-tailed Student's t-test
was used to compare individual groups. The in vivo inﬂux studywas
analyzed by performing a one-way ANOVA, followed by a Tukey's
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ing a ManneWhitney U test. P < 0.05 was considered signiﬁcant.3. Results
3.1. RP105 deﬁciency results in reduced plaque size
During atherosclerosis, RP105 was seen to be signiﬁcantly
upregulated during early lesion development, which directly mir-
rors the upregulation of TLR4 expression (Suppl. Fig. 2A). In order to
investigate the effect of RP105 deﬁciency on early atherosclerosis,
LDLr//RP105/mice and LDLr/mice on a high fat diet received
perivascular collars around the carotid arteries. Weight and
cholesterol levels did not differ between the groups (Fig.1(A)). FACS
analysis of the blood at sacriﬁce revealed no changes in the per-
centage of monocytes (CD11bþLy6Glow cells), neutrophils
(CD11bþLy6Ghigh cells) or in the percentage of B cells (CD19þ cells)
(Fig. 1(B)).Fig. 2. Lesional macrophages are decreased in LDLr¡/¡/RP105¡/¡ mice. Plaque morpholo
cells. No differences were found between the percentage of smooth muscle cells (ASMA, A),
(C and D). Macrophage content in LDLr//RP105/ mice was signiﬁcantly reduced compar
(100). N ¼ 12 mice/group. *P < 0.05. A 2-tailed Student's t-test was used to compare indiAnalysis of plaque size, using hematoxylin-phloxine-saffron
(HPS) stained sections, revealed a marked decrease in atheroscle-
rotic lesion formation in the RP105 deﬁcient mice (LDLr/:
20.66 ± 4.7*103 mm2; LDLr//RP105/: 8.7 ± 2.3*103 mm2;
P < 0.05; Fig. 1(C)). Medial thickness remained unaltered between
the two groups (LDLr/: 55.0 ± 2.8*103 mm2; LDLr//RP105/:
49.6 ± 3.6*103 mm2; P ¼ 0.25).3.2. Lesional macrophages are decreased in LDLr//RP105/ mice
Plaque compositionwas further analyzed by staining for smooth
muscle cells, collagen content, mast cells, and macrophages. The
percentage of intimal smooth muscle cells of total plaque area was
not affected by RP105 deﬁciency (LDLr/: 11.1% ± 2.6%; LDLr/
/RP105/: 18.9% ± 3.8%; Fig. 2(A)) and also, Sirius red staining
revealed no differences in relative collagen content (LDLr/:
16.2% ±1.9%; LDLr//RP105/: 17.8% ± 1.6%; Fig. 2(B)). The num-
ber of mast cells in the perivascular tissue and their activation
status, as measured by the amount of granules present in thegy was analyzed by staining for macrophages, collagen, smooth muscle cells and mast
collagen content (Sirius Red, B), or perivascular mast cell numbers and activation status
ed to LDLr/ mice (MAC3, E). Micrographs show representative images of both groups
vidual groups.
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(D)). However, we observed a profound 40% decrease in lesional
macrophage content (as percentage of total plaque area, LDLr/-:
26.0% ± 3.7%; LDLr//RP105/: 15.6% ± 2.3%; P < 0.05; Fig. 2(E)).
Interestingly, RP105 expression in the atherosclerosis time course
was seen to increase mostly during the ﬁrst two weeks after collar
placement, which was highly comparable to the expression pat-
terns of monocyte/macrophage markers during lesion develop-
ment (Suppl. Fig. 2B), suggesting that intra-lesional RP105 is pre-
dominantly monocyte/macrophage derived.3.3. Decrease in peritoneal B cells and reduction in plasma IgE and
IgM levels
Since RP105 deﬁciency has been described to affect B cell acti-
vation and proliferation [23], we further analyzed the percentage
and subpopulations of B cells in the peritoneum by FACS analysis.
The percentage of B cells (CD19þ cells) was signiﬁcantly decreased
inmice deﬁcient for RP105 (LDLr/: 68.1% ± 3.6%; LDLr//RP105/
: 51.4% ± 4.1%; P < 0.05; Fig. 3(A)). B cell subsets, determined as a
percentage of the total B cell population, did not differ between the
groups (Fig. 3(B) and (C)). Also, mast cell content did not differ
(Fig. 3(D)). RP105 deﬁciency markedly reduced plasma IgE and IgM
levels, while not affecting plasma IgG1 or IgG2a concentrations
(Fig. 3(E)e(H)).3.4. In vivo migration is impaired in RP105 deﬁcient monocytes
In order to elucidate the mechanism behind the decreased
amount of lesional macrophages found in vivo, we aimed to
investigate whether monocyte migration was disturbed in mice
lacking RP105. Monocyte inﬂux to the peritoneum was measured
after thioglycollate injection in LDLr/ and LDLr//RP105/mice
by staining for CD11bþLy6G cells. Interestingly, monocyte migra-
tion in RP105 deﬁcient mice is markedly disturbed compared to
LDLr/ mice as revealed by FACS analysis (LDLr/: 31.3 ± 1.3 fold
increased inﬂux; LDLr//RP105/: 11.9 ± 3.7 fold increased inﬂux;
P < 0.001; Fig. 4(A)). Concomitantly, a decrease in the percentage of
CCR2 positive monocytes was observed in LDLr//RP105/ miceFig. 3. Decrease in peritoneal B cells and reduction in plasma IgE and IgM levels. B ce
compared to LDLr/ mice (A). No changes were observed between the percentage of perit
(percentage of IgMIgDþ cells within CD19þ cells) (C). The percentage of mast cells in the pe
IgE (E) and IgM (F) was detected in LDLr//RP105/mice at time of sacriﬁce, while no chan
2-tailed Student's t-test was used to compare individual groups.P < 0.05; Fig. 4(B)). No changes were detected in neutrophil inﬂux
(Fig. 4(C)).3.5. Decrease of CCR2þ LDLr//RP105/ monocytes after LPS
activation in vitro
To further investigate the effects of RP105 deﬁciency on
monocyte migration we observed in vivo, we determined the
expression of chemokine receptors CCR2 and CCR5 on bone
marrow derived monocytes in vitro. FACS analysis showed an
increased percentage of CCR2þ positive LDLr//RP105/ mono-
cytes compared to LDLr/ monocytes when unstimulated. How-
ever, after stimulation with 1 or 10 ng LPS, a signiﬁcant dose-
dependent decrease in the percentage of CCR2þ cells was
observed in the LDLr//RP105/monocyte population, which did
not occur in LDLr/ monocytes (Fig. 5(A)). Moreover, after stimu-
lation with 10 ng LPS, the percentage of CCR2þ LDLr//RP105/
monocytes was signiﬁcantly reduced compared to LDLr/ mono-
cytes. The percentage of CCR5 positive LDLr//RP105/ mono-
cytes was increased compared to monocytes from LDLr/ mice,
also after stimulationwith 1 ng LPS. However 10 ng LPS stimulation
did not result in changes between the two groups (Fig. 5(B)).
Expression of CCR2 at mRNA level after LPS stimulation showed
a decrease in both LDLr/ and LDLr//RP105/ monocytes,
however this decrease was more pronounced in LDLr//RP105/
monocytes (Fig. 5(C)). After stimulation with 1 ng LPS, CCR2
expression was signiﬁcantly decreased in LDLr//RP105/
monocytes compared to LDLr/ monocytes. Stimulation with
10 ng LPS resulted in such a strong reduction of CCR2 expression
that no signiﬁcant differences were detectable any more between
the two groups. We have measured the expression of CCR1, CCR5
and CX3CR1 in in vitro cultured LDLr/ and LDLr//RP105/
monocytes as well, which did not show a similar downregulation
after LPS stimulation as CCR2 (Suppl. Fig. 4). CX3CR1 gene
expression is somewhat reduced in LDLr//RP105/ mice, sug-
gesting that RP105 deﬁciency may affect this chemokine receptor
as well, however not to the extent of CCR2.lls in the peritoneum (CD19þ) were signiﬁcantly decreased in LDLr//RP105/ mice
oneal B1 cells (percentage of CD5þCD4IgMþ cells within CD19þ cells) (B) and B2 cells
ritoneum did not differ between the two groups (D). A signiﬁcant reduction of plasma
ges were seen in IgG1 (G) or IgG2a (H) levels. N ¼ 12 mice/group. *P < 0.05, **P < 0.01. A
Fig. 4. In vivo migration is impaired in LDLr¡/¡/RP105¡/¡monocytes. FACS analysis
showed a signiﬁcant reduction of monocyte inﬂux to the peritoneum in LDLr/
/RP105/ mice compared to LDLr/ mice after intra-peritoneal injection of thio-
glycollate, depicted as a fold change compared to PBS injection (A). Also, decreased
inﬂux of CCR2þ monocytes was observed in LDLr//RP105/ mice (B). No changes
were found in the relative inﬂux of neutrophils (C). N ¼ 5 mice/group. *P < 0.05
compared to thioglycollate treated LDLr/ mice. ***P < 0.001 compared to thio-
glycollate treated LDLr/ mice. A one-way ANOVA was performed, followed by a
Tukey's multiple comparison test.
A. Wezel et al. / Atherosclerosis 238 (2015) 132e139 1373.6. CCR2 expression in atherosclerotic plaques
Atherosclerotic plaques of LDLr/ and LDLr//RP105/ mice
were stained for CCR2 to determine whether expression of this
chemokine receptor within the lesion is altered by RP105 deﬁ-
ciency. No signiﬁcant differences were observed in CCR2 staining
(as percentage of intimal area) between the LDLr//RP105/ and
LDLr/ mice (LDLr/: 29.9% ± 4.2%; LDLr//RP105/:
21.6% ± 2.5%; P ¼ 0.1; Suppl. Fig. 3). To determine whether RP105
deﬁciency affected circulating levels of MCP-1, one of the most
important ligands for CCR2, we analyzed plasma MCP-1 levels in
LDLr/ and LDLr//RP105/mice at time of sacriﬁce. We did not
observe any changes between the two groups (Suppl. Fig. 5).4. Discussion
The current study is the ﬁrst to demonstrate that expression of
RP105 is upregulated early in atherogenesis, as shown in the time
course experiment, and that total body RP105 deﬁciency attenuates
early atherosclerotic lesion formation via decreased monocyte
inﬂux. Also, we show that LPS stimulation of RP105 deﬁcient
monocytes results in a downregulation of the chemokine receptor
CCR2, which may be the cause of the observed reduction in
migratory capacity of RP105 deﬁcient monocytes.
In the current study, the most prominent ﬁnding is a 40%
reduction in lesional macrophage content in LDLr//RP105/
mice resulting in reduced lesion development as compared to
LDLr/ controls fueling the hypothesis that a disturbed monocyte
inﬂux into the vessel wall underlies the reduction in atherosclerosis
in LDLr//RP105/ mice. Indeed, inﬂux of LDLr//RP105/
monocytes into the peritoneum was signiﬁcantly decreased
compared to LDLr/ monocytes. In vitro, the percentage of CCR2þ
LDLr//RP105/ monocytes was signiﬁcantly reduced after LPS
stimulation, while the relative expression of CCR2 on LDLr/
/RP105/ monocytes, as compared to LDLr/ monocytes, was
also signiﬁcantly reduced. These results indicate that CCR2 may be
one of the chemokine receptors involved in decreased monocyte
migration in LDLr//RP105/mice, which leads to the decrease in
early lesion formation with reduced macrophage content observed
in vivo [24,25]. In addition, future research may point to regulation
of other chemokine receptors in RP105 deﬁcient monocytes as well.
Previously, we have shown that lethally irradiated atheroscle-
rosis prone LDLr/ mice receiving RP105/ bone marrow display
reduced lesion development, in which the atheroprotective effects
were attributed to a reduction in B cell numbers, and in particular of
B2 cells [19]. However, in that study, leukocyte speciﬁc RP105
deﬁciency was investigated, thereby excluding effects that RP105
deﬁciency may have on non-myeloid cells, such as on vascular
smooth muscle cells. In fact, it has also been previously established
that RP105 deﬁciency results in increased neointima formation via
enhanced smooth muscle cell proliferation [18]. Therefore, in the
current study, we aimed to investigate total body RP105 deﬁciency,
in order to take into account the effects of both myeloid and non-
myeloid deletion of RP105. Our results indicate that smooth mus-
cle cell derived RP105 does not signiﬁcantly impact atherosclerotic
lesion development, as smooth muscle cell and collagen staining
failed to show any signiﬁcant changes between plaques of LDLr/
and LDLr//RP105/ mice. Similar to the previous study we
observed a decrease in B cells; however, this was not as prominent
and the ratio between B cell subsets remained unaltered. This
reduction of B cells observed in the current study is reﬂected by
decreased levels of total plasma IgE and IgM. Previous studies have
shown that B cells are hardly present within the atherosclerotic
plaque or perivascular tissue [26], suggesting that effects B cells can
have on the plaquemay be pre-dominantly systemically or indirect.
For example, it has been described that IgM speciﬁc for ox-LDL may
be atheroprotective by limiting accumulation of apoptotic cells and
inhibiting inﬂammatory gene expression [27]. In the present study
we measured only total IgM, instead of oxLDL speciﬁc IgM and
therefore, in this experimental setup, it remains unclear whether
the observed reduction of total plasma IgM contributed to lesion
formation.
Inﬂux of monocytes at predisposed areas into the vessel wall is
considered an important initial step in atherosclerosis [3e5]. Sup-
pression of monocyte recruitment in atherogenesis has been
shown to result in reduced plaque size and altered plaque
composition, however, these effects were not seen when mono-
cytes were reduced in late stage atherosclerosis, stressing the
importance of monocyte inﬂux in early atherogenesis [28].
Fig. 5. Decrease in CCR2þ LDLr¡/¡/RP105¡/¡ monocytes after LPS activation in vitro. FACS analysis of in vitro cultured LDLr//RP105/ monocytes stimulated with 1 or 10 ng
LPS revealed a signiﬁcant dose-dependent decrease in the percentage of CCR2þ RP105 deﬁcient monocytes. After stimulation with 10 ng LPS, the percentage of CCR2þ monocytes
was signiﬁcantly reduced in LDLr//RP105/ monocytes compared to control LDLr/ monocytes (A). The percentage of CCR5þ LDLr//RP105/ monocytes was increased
compared to LDLr/ monocytes in the unstimulated control and after stimulation with 1 ng LPS stimulation, 10 ng LPS stimulation did not result in changes between the two
groups (B). LPS stimulation decreased the relative CCR2 expression in both LDLr/ and LDLr//RP105/ monocytes; however, after stimulation with 1 ng LPS, CCR2 expression
was signiﬁcantly decreased in LDLr//RP105/ monocytes compared to LDLr/ monocytes (C). N ¼ 4. #P < 0.05 compared to LDLr/ monocytes; *P < 0.05 compared to
unstimulated monocytes; ***P < 0.001 compared to unstimulated monocytes. A 2-tailed Student's t-test was used to compare individual groups.
A. Wezel et al. / Atherosclerosis 238 (2015) 132e139138Intriguingly, we have recently found that RP105 deﬁcient mono-
cytes display signs of increased activation and disturbed migration
towards the adductor muscle in hind limb ischemia [29]. This led to
the hypothesis that disturbed monocyte migration into the vessel
wall in LDLr//RP105/ mice may be the cause of decreased
atherosclerotic lesion formation observed in the current study.
Monocyte migration occurs via the well-known chemokine re-
ceptors CCR1, CCR2, CCR5 and CX3CR1 [6,30]. Already 15 years ago
it has been shown that lesion development in apoE/ mice deﬁ-
cient for the CeC chemokine receptor CCR2 is markedly decreased,
demonstrating an important role of CCR2 in atherosclerosis
[25,26,31,32]. Interestingly, activation of monocytes via the TLR4
route has been shown to downregulate chemokine receptors, in
particular CCR2 [33e36]. In the current study, we have also
demonstrated that stimulation of monocytes with LPS, the most
important activator of TLR4, decreases both the percentage of CCR2
positive monocytes as well as the relative expression of CCR2.
Intriguingly, this effect was more pronounced in monocytes deﬁ-
cient for RP105. RP105 is thought to act as a negative regulator in
dendritic cells and macrophages via direct interactionwith TLR4 on
the cell membrane [16]. RP105 expression has shown to inhibit
TLR4-driven NF-kB transactivation and IL-8 production by HEK293,
while lack of RP105 results in increased activation and cytokine
release [37]. Therefore, we speculate that the more pronounced
decrease of CCR2 in RP105 deﬁcient monocytes may be due to
increased signaling via the TLR4 route.
CCR2 staining in the atherosclerotic plaques was not signiﬁ-
cantly reduced in LDLr//RP105/ mice as compared to LDLr/
mice, despite changes in CCR2 expression in LDLr//RP105/
monocytes. Apart from the difﬁculty to detect subtle differences in
protein expression levels by immunohistochemistry, this may also
be due to the fact that monocytes, once arrived in the plaque,
differentiate into macrophages and thereby alter expression of re-
ceptors, and in particular of chemokine receptors [38]. CCR2expression may thus be altered on LDLr//RP105/ monocytes,
but upon arrival in the vessel wall and subsequent differentiation,
these changes in chemokine receptor expression become less
pronounced. Further research is aimed at the elucidation of
mechanisms causing disturbed CCR2 expression upon RP105 deﬁ-
ciency in atherosclerosis and other inﬂammatory disorders.
In conclusion, we here show that LDLr//RP105/ mice
develop reduced early atherosclerotic plaques with a marked
decrease in lesional macrophages. Our data suggest that this is due
to disturbed migration of RP105 deﬁcient monocytes, caused by a
downregulation of CCR2.
5. Conclusions
In this study, we found a signiﬁcant upregulation of RP105
expression in early atherogenesis. Total body RP105 deﬁciency in
LDLr//RP105/ mice resulted in a marked reduction of athero-
sclerotic lesion size, compared to control LDLr/mice. No changes
were observed in the smooth muscle cell percentage in the plaque;
however, macrophage content was signiﬁcantly reduced in LDLr/
/RP105/ mice. We deliver in vivo experimental proof that
monocyte migration is reduced in RP105 deﬁcient mice, whichmay
explain the reduction in lesional macrophages. Furthermore,
in vitro investigations show that this decreased migratory capacity
may be due to a more pronounced downregulation of CCR2 in
LDLr//RP105/ monocytes compared to LDLr/ monocytes, af-
ter LPS stimulation. These data may thus provide a novel mecha-
nism via which RP105 deﬁciency may attenuate atherosclerosis.
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